Key facts
- It has raised $9.2M; the latest was Early Stage VC in Oct 2025.
- Notable investors include Creative Destruction Lab, Brandenburg Kapital, Ascenion, Bundesministerium für Bildung und Forschung, HIL-INVENT — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Captain T Cell
- ·The full record, as it builds
Funding rounds
No funding rounds for Captain T Cell are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Captain T Cell
Operator of a T-cell therapy firm intended for drug discovery. The company develops efficacy-enhanced therapies against solid tumors not addressed by existing treatments, enabling patients to treat their cancer diagnosis.
- Sector
- Healthcare
- HQ
- Berlin, Germany
- Founded
- 2019
- Employees
- 10
- Website
- captaintcell.com/
- Ownership
- Privately Held (backing)
Captain T Cell doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Captain T Cell shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Captain T Cell in its N-PORT filings yet. We sweep new filings monthly.